Inclusion Criteria:

- Have commercially manufactured brexucabtagene autoleucel that does not meet commercial
release criteria but does meet Kite clinical trial release criteria.

- Females of childbearing potential must have a negative serum or urine pregnancy test
(females who have undergone surgical sterilization or who have been post-menopausal
for at least 2 years are not considered to be of childbearing potential).

- Deemed medically fit and stable to receive the product per the investigator's
evaluation.

- Repeat leukapheresis is not feasible per the investigator's assessment.

- Be diagnosed with 1 of the approved labeled indications for brexucabtagene autoleucel
that is intended for release.

- In the Investigator's opinion, there is no satisfactory alternative therapy available
to the individual.

Exclusion Criteria:

- History of severe immediate hypersensitivity to any drugs or metabolites of similar
chemical classes as brexucabtagene autoleucel.

- Uncontrolled active infection or inflammation per physician assessment.

- Primary central nervous system (CNS) lymphoma.

Eligibility last updated 5/4/23. Questions regarding updates should be directed to the study team contact.